<a href="https://www.fiercebiotech.com/medtech/resmed-snaps-noctrix-health-340m-sleep-tech-deal" hreflang="en">ResMed snaps up Noctrix Health in $340M sleep tech deal</a>
ResMed has acquired Noctrix Health for $340 million, integrating its Nidra Tonic Motor Activation therapy, a noninvasive treatment for restless legs syndrome, into ResMed's sleep health portfolio. This acquisition aims to expand ResMed's offerings beyond sleep apnea and enhance its digital health capabilities.
ResMed's $340 million acquisition of Noctrix Health, adding the FDA De Novo-classified Nidra neuromodulation device for restless legs syndrome, exemplifies the strategic growth in integrating wearable therapeutics with digital health platforms. This move not only strengthens ResMed's portfolio beyond CPAP-centric offerings but also highlights the potential for expanding home-based, digitally connected healthcare solutions, signaling an actionable investment opportunity in the convergence of wearables and long-term disease management platforms.